SCHEMBL22265306

SCHEMBL22265306

CC(C)(C)c1cccc(Nc2ccc(C#N)cn2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.47
TNNI3K Q59H18 1/20 0.47
MAPT P10636 2/20 0.44
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GAA P10253 1/20 0.43
THRB P10828 1/20 0.42
CCR6 P51684 2/20 0.41
CSNK1D P48730 2/20 0.41
CSNK1G2 P78368 2/20 0.41
GRM4 Q14833 1/20 0.41
JAK2 O60674 1/20 0.41
TYK2 P29597 1/20 0.40
PDE4D Q08499 1/20 0.40
KDM1A O60341 1/20 0.40
MAOB P27338 1/20 0.40
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10549553 0.78 ABCG2 (0.53) MAPTKDM4EMEN1KMT2AGAA
SCHEMBL4778121 0.74 EGFR (0.51) EGFRTNNI3KMAPTKDM4EMEN1
SCHEMBL28416838 0.74 GRM4 (0.52) EGFRTNNI3KMAPTKDM4EMEN1
SCHEMBL29408383 0.74 GRM4 (0.52) EGFRTNNI3KMAPTKDM4EMEN1
SCHEMBL14184982 0.73 MEN1 (0.42) KDM4EMEN1KMT2AGAACCR6
SCHEMBL22575269 0.73 CYP11B2 (0.50) MEN1KMT2AGAAABCG2
SCHEMBL22280459 0.72 ALDH1A1 (0.48) KDM4EGAACCR6CSNK1DCSNK1G2
SCHEMBL22265526 0.72 KDM4E (0.46) EGFRTNNI3KMAPTKDM4EMEN1
SCHEMBL22265527 0.72 KDM4E (0.46) EGFRTNNI3KMAPTKDM4EMEN1
SCHEMBL21625856 0.72 KIF11 (0.54) EGFRTNNI3KMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-31 US disclosed
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed
EP-3914592-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2021-12-01 EP disclosed
WO-2020154431-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY LYNCH KEVIN R (US) 2020-07-30 WO disclosed
WO-2020154431-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY LYNCH KEVIN R (US) 2020-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 EGFR 2659/4885TNNI3K 1011/4885MAPT 22/4885
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy SPNS2, SLC20A2, S1PR2 EGFR 4153/4885TNNI3K 2215/4885MAPT 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.